Tarsus Pharmaceuticals, Inc.
TARS
$58.85
$2.243.96%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | 19.03% | -8.68% | 1.31% | 29.65% | 6.83% |
Total Depreciation and Amortization | -1.52% | 6.48% | 52.11% | 18.83% | -11.48% |
Total Amortization of Deferred Charges | 5.04% | 0.72% | 6.98% | 27.72% | -11.40% |
Total Other Non-Cash Items | 16.07% | -5.06% | -5.57% | -22.27% | 34.93% |
Change in Net Operating Assets | -756.28% | 66.65% | -172.42% | -22.86% | 219.36% |
Cash from Operations | -42.30% | 6.90% | -156.38% | 39.93% | 61.88% |
Capital Expenditure | -69.66% | -719.44% | 74.47% | 72.86% | -497.13% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -47.60% | 42.27% | -1,844.93% | 108.64% | 61.31% |
Cash from Investing | -47.97% | 41.35% | -2,004.54% | 107.72% | 60.36% |
Total Debt Issued | -- | -- | -- | -100.00% | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -98.57% | 4,565.60% | 331.71% | -74.70% | -97.30% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | 100.00% | 99.89% | -477.59% |
Cash from Financing | -98.57% | 4,565.60% | 358.06% | -98.49% | -61.09% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -197.74% | 202.71% | -1,513.69% | 61.26% | 59.64% |